Drug-induced Parkinson’s disease modulates protein kinase A and Olfactory Marker Protein in the mouse olfactory bulb

Carla Mucignat1,2* and Antonio Caretta2,3

Abstract

Background: Olfaction is often affected in parkinsonian patients, but dopaminergic cells in the olfactory bulb are not affected by some Parkinson-inducing drugs. We investigated whether the drug MPTP produces the olfactory deficits typical of Parkinson and affects the olfactory bulb in mice.

Findings: Lesioned and control mice were tested for olfactory search, for motor and exploratory behavior. Brains and olfactory mucosa were investigated via immunohistochemistry for thyrosine hydroxylase, Olfactory Marker Protein and cyclic AMP-dependent protein kinase as an intracellular pathway involved in dopaminergic neurotransmission. MPTP induced motor impairment, but no deficit in olfactory search. Thyrosine hydroxylase did not differ in olfactory bulb, while a strong decrease was detected in substantia nigra and tegmentum of MPTP mice. Olfactory Marker Protein decreased in the olfactory bulb of MPTP mice, while a cyclic AMP-dependent protein kinase increased in the inner granular layer of MPTP mice.

Conclusions: MPTP mice do not present behavioural deficits in olfactory search, yet immunoreactivity reveals modifications in the olfactory bulb, and suggests changes in intracellular signal processing, possibly linked to neuron survival after MPTP.

Keywords: Parkinson’s disease, Animal models, Olfactory bulb, Protein kinase A

Background

In human Parkinson’s disease (PD) patients, an impairment in the sense of smell and in olfactory structures is often reported [1, 2]. Neurons of the olfactory system are affected by degenerative changes, like the presence of Lewy bodies [3, 4] at an early stage, when motor deficits are not yet apparent: hence, modifications of the olfactory system can be used for early PD diagnosis [5].

Olfactory processing is linked to dopaminergic signaling, which has a prominent role in the olfactory bulb (OB) circuitry: dopamine D2 receptors in terminals of olfactory neurons and in dendrites of mitral/tufted cells modulate glutamate release, and in terminals of GABAergic/dopaminergic cells they modulate GABA and dopamine release [6, 7]. Moreover, in olfactory neurons dopamine inhibits adenylyl cyclase [8] and in OB granule cells activation of D1 receptors modulates GABA A receptors through the cAMP/protein kinase A (PKA) activation [9].

Dopamine and cAMP signalling pathway mutually interact also in brain nuclei involved in PD. PKA stimulates dopamine uptake [10], and activates tyrosine hydroxylase (TH) [11]. On striatal GABAergic neurons, D1 receptor activates PKA, that phosphorylates glutamate NMDA receptors [12]. PKA regulates dopamine physiology and modulates the activity of proteins involved in PD, including LRRK2, alpha-synuclein, tau and TH [13–16].

The OB is one of the main dopaminergic nuclei in the brain [17]. It receives axons from new receptors that continuously differentiate in the olfactory neuroepithelium, and new cells from the subventricular zone, that become...
periglomerular and granular cells. Dopamine is a paracrine signal for differentiation of subventricular stem cells [18], therefore a deficit in dopaminergic cells acts also on neuron turnover in the OB [19]. Moreover, cAMP regulates differentiation and survival of new neurons in the OB [20].

To better understand whether mesencephalic and OB dopaminergic neurons respond differentially to chemical insults, we investigated the changes in TH and PKA in the OB of the murine PD MPTP (1-methyl-4-phenyl,1,2,3,6-tetrahydropyridine) model.

Methods
Animals and treatment
Experiments were authorized according to the directive 86/609/EEC. Twelve C57BL/6j male mice 4 months old were used (Charles River, Lecco, Italy). MPTP hydrochloride (Sigma, Milan, Italy; 15 mg/kg in 0.9% NaCl, n = 6) or saline solution (0.9% NaCl, n = 6) was i.p. injected, four times every 2 h.

Behavioral tests
Mice were weighted, evaluated for neurologic deficits and tested 5 days before and five after injections. On the day of injections, tests started 1 h after the last injection.

The open field test measures locomotion and exploration. The mouse was introduced in a cage (55 × 33 × 20 cm) for 10 min and videotaped. A software (Smart 2.5, 2B Biological Instruments, Varese, Italy) calculated distance, resting time, and number of rearings on the walls [21]. Thigmotaxis was quantified by measuring the permanence time and the time spent resting in proximity of the walls, excluding a central area (35 × 16 cm).

The pole test detects bradykinesia [22]: the mouse was placed on the top of a pole (1.5 cm diameter, 50 cm height). The time until it reached the floor was recorded (maximum 3 min).

The grip test [22] consisted in placing forepaws on the middle of a wire, 2 mm × 90 cm, 15 cm above the floor: the time to fall down or to reach the lateral platforms was recorded (maximum 3 min).

The cookie-finding test evaluates olfactory function [21]. On the second day pre-injection and after injection, mice were overnight deprived of food then put in a cage (42 × 25 × 15 cm) with a food pellet buried under the sawdust: the latency to discover it was recorded within 5 min. The test was repeated after 1 h with a pellet in a visible position to control for motivation to eat. The test was not repeated every day in order to avoid unnecessary stress due to overnight food restriction.

The tests were repeated on all mice up to day 3 post-injection, then half of the mice were sacrificed, on day 4 and 5 three mice were tested in each group. The data collected before treatment were compared to those collected after injection: data were analyzed with mixed design analysis of variance (ANOVA, factors Group: control/MPTP; Day: pre- vs. post-treatment) and post hoc Newman–Keuls, using Statistica 5 software (www.statsoft.com). The significant level was p < 0.05. Data from behavioral tests are presented as mean ± SEM.

Immunohistochemistry
Three or 5 days after injection, mice were euthanized (Tanax 20 mg/kg, i.p.). After preincubation of paraffin-embedded sections for 1 h with 2% bovine serum albumin, nose and brain sections were incubated overnight with Olfactory Marker Protein (OMP) antibody (Wako, Neuss, Germany, 1:600); brains were also incubated with TH (Santa Cruz Biotechnology, Heidelberg, Germany, 1:100), or synaptophysin antibodies (Sigma, Milan, Italy, 1:100). Frozen sections were washed for 30 min in 2% Triton-X100, fixed for 1 min in formalin at 37 °C and incubated overnight with anti- murine PKA RIIalpha (Santa Cruz Biotechnology, Heidelberg, Germany, 1:200); adjacent sections were incubated with 100 nM 8-thioacetamido-fluorescein-cAMP (SAF-cAMP) to visualize PKA RI [23]. Secondary antibodies (Sigma, Milan, Italy; or Molecular Probes, Milan, Italy) 1:400 were incubated 1 h at 37 °C. Slides were evaluated independently with a Leica microscope (objectives: 20×, 40×, 100×) by two observers on a semiquantitative 5-step scale. Unaltered images obtained using the same conditions were mounted with Corel Draw 12 (Corel Corporation, Ottawa, Canada).

Results
Behavioral tests
Mice did not differ in body weight, before and after the treatment: before treatment, 25.1 ± 1.1 versus 24.9 ± 1.1 g for controls and MPTP-treated, respectively; after treatment: 24.2 ± 1.1 versus 24.4 ± 1.2 g for controls and MPTP-treated, respectively.

All mice during the first and second repetition of the tests improved their performance, to reach a steady-state performance before the treatment (Fig. 1). After the treatment, MPTP-treated mice displayed some deficits, in comparison to controls and to their pre-treatment scores.

The Cookie-finding test did not differ between controls and MPTP mice when food was hidden. Only the factor Day was significant, F(1,10) = 6.995, p < 0.05: both groups after treatment were slower in retrieving hidden food, possibly as a consequence of the stress imposed by injections. MPTP mice did not display any obvious deficit with visible food. All mice were able to retrieve the food in both invisible and visible conditions.
A reduction in motor activity after MPTP was apparent in the open field, with a decrease in the distance travelled [Group: $F(1,10) = 20.094$, $p < 0.005$ controls: $3136.9 \pm 214.8$ cm, MPTP: $1776.4 \pm 214.3$ cm] and in the number of rearings; the significant interaction Group $\times$ Day, $F(1,10) = 7.817$ $p < 0.05$, showed that only MPTP mice performed less rearings after the treatment, $28.6 \pm 5.4$ and $36.8 \pm 6.4$ rearings for controls ($p = 0.25$),
and 21.8 ± 5.6 versus 3.0 ± 1.8 rearings in MPTP mice (p < 0.005). The resting time differed between groups, F(1,10) = 22.834, p < 0.001, with MPTP mice resting for a longer time compared to controls, 550.0 ± 7.6 versus 497.2 ± 7.9 s.

By analysing only to the zone adjacent to the walls, the factor Day was different, F(1,10) = 71.838, p < 0.0001: both control and MPTP mice spent a longer time (including walking and resting) along the walls after the treatment, compared to the day before treatment (p < 0.005). This may be due to the stress of injections. Considering only the time spent resting in the proximity of the walls, both the factors and the interaction were significant. The interaction Group × Day, F(1,10) = 9.952 p < 0.02, showed that while controls did not vary (360.2 ± 16.3 vs. 387.8 ± 17.5 s, respectively), MPTP mice spent a longer time resting along the border after the treatment (386.6 ± 16.9 vs. 522.5 ± 29.6 s before and after the treatment respectively, p < 0.001).

In the pole test, the factor Day was significant, F(1,10) = 13.673, p < 0.005, and the interaction tended to significance, F(1,10) = 4.749, p = 0.054: only MPTP mice were slower in reaching the ground after the treatment (7.3 ± 2.7 vs. 62.1 ± 12.2 s), while controls did not vary significantly (11.8 ± 7.0 vs. 26.0 ± 9.0 s).

In the grip test, the time to reach one end was different: the significant interaction, F(1,10) = 12.597 p < 0.01, showed that only MPTP mice took longer to reach the extremity after the treatment (24.1 ± 6.7 vs. 156.6 ± 23.3 s in MPTP mice, p < 0.001, and in controls: 25.5 ± 5.7 vs. 49.8 ± 20.5 s). Only mice treated with MPTP fell down (5 out of 6 mice), as shown by the interaction Group × Day, F(1,10) = 24.217, p < 0.001.

**Immunohistochemistry**

Data on immunohistochemistry are summarized in Table 1 and representative sections are shown in Fig. 2. As expected, TH was reduced in substantia nigra after MPTP (Fig. 2a, b), but did not change in the OB (Fig. 2c, d).

In the nose of both groups, OMP labelling was prominent in olfactory neurons, olfactory fila, and vomeronasal neurons. However, the olfactory nerve and glomeruli in the main OB were consistently fainter in MPTP mice (Fig. 2e, f). This difference was not present in the accessory OB. Synaptophysin did not change in both control and MPTP mice.

No obvious modification was apparent in PKA RI, yet 3 days after MPTP PKA RII was brighter in the inner granular layer of the main OB and in the granule cells of the accessory OB, compared to controls (Fig. 2g, h, see also [23]). Five days after MPTP, this difference was less apparent, the most intense granule cells were confined immediately below the mitral cell layer, while the inner granular layer was very faint.

**Discussion**

Multiple factors contribute to the onset and progress of PD, that initially targets few susceptible neuron types in motor nuclei of glossopharyngeal and vagus nerves, and in the anterior olfactory nucleus [2, 3, 24]. Many animal models are available for mimicking PD landmarks, however none can reproduce in full the human pathology. The picture is even more complicated by the presence of both motor and non-motor symptoms, whose assessment in animal models may be difficult and need careful overall interpretation (for a review, see [25]). We choose the MPTP model because we were interested in olfactory dysfunctions, which are a hallmark of early PD stages. MPTP administered acutely in mice can reproduce early stages of PD [26], however, it is not sufficient for fully exploring PD, since MPTP-injected mice recover spontaneously, which precludes the study of pharmacological interventions. Moreover, various strains of mice show different sensitivity to MPTP.

### Table 1 OMP and TH immunostaining

|                | Control | Day 3 | Day 5 |
|----------------|---------|-------|-------|
| **OMP**        |         |       |       |
| Olfactory nerve| +++     | +     | +     |
| Olfactory glomeruli | +++   | +     | +     |
| **TH**         |         |       |       |
| Olfactory bulb | ++      | ++    | ++    |
| Substantia nigra | ++++  | ±     | ±     |

No labeling (−); faint labeling (+); moderate labeling (+); intense labeling (+++); very intense labeling (++++)

(See figure on next page.)

**Fig. 2** Immunohistochemistry on horizontal brain sections. Bar 200 μm for a, b, e, f. 50 μm for c, d, g, h. a–d TH immunolabelling: a Substantia nigra/ventral tegmental area appear labelled in a control mouse; caudal on the right. ip interpeduncular nucleus, sn substantia nigra, sum supramammillary nucleus, vta ventral tegmental area. b The same area is almost unlabelled in a MPTP mouse, 3 days after injections; rostral on the right. c, d Periglomerular cells are similarly labelled in a control mouse (c) and in a MPTP-treated mouse (d); 3 days after injections; caudal on top right e, f OMP immunoreactivity in the olfactory bulb of a control (e) and a MPTP mouse (f); 3 days after injections. In the control mouse, the olfactory nerve and glomerular layer are labelled, also the accessory olfactory bulb glomerular layer is labelled. Caudal on the lower right g, h RII immunoreactivity in the main olfactory bulb of a control (g) and a MPTP-treated mouse, 3 days after injections. Caudal on the top, lateral on the left: m mitral cell layer, ig inner granular layer
PD implies a complex imbalance of the dopaminergic system. However, not all dopaminergic neurons in the brain are equally affected by degeneration.

Here, in MPTP mice olfactory search behavioural performance is normal, yet some modifications can be detected via immunoreactivity in the OB.

MPTP in mice induces both behavioral and neurochemical changes that mimic human PD: altering free radicals quenching and reducing TH and dopamine transporter in the substantia nigra and striatum [27] result in motor impairments, bradykinesia and catalepsy [22]. However, MPTP does not worsen olfaction in both humans and mice [28, 29]. In our experiment, mice were impaired in motor performance, as shown by short travelled distance and less rearings on the walls—an increase in the rearings is used as an index of anxiety. However, MPTP mice performed similarly to controls in olfactory retrieving, which also included motor performance. This may be due to differential involvement of the motivational system, which is conceivably more activated in discovering and reaching food items. PD patients are impaired in the motor but also in cognitive/integrative levels of motor control [30], and often show apathy and indecisiveness [31]; similarly, our mice move under a sufficiently strong drive. However, their good performance in the cookie-finding test does not imply a normal olfactory function. This test involves exposure to above-threshold stimuli: it is possible that MPTP mice show subtler olfactory deficits. Noteworthy in a genetic PD model, mice were able to detect and habituate to odors, but showed deficits in more stringent olfactory tests [32].

MPTP modifies the expression of several proteins: in the striatum it reduces dopamine, TH, dopamine transporter, vesicle monoamine transporter and alpha-synuclein, while monoaminooxidase A and B and catechol-O-methyl-transferase remain unchanged [33]. Reduced TH levels were apparent in our MPTP mice in the brainstem dopaminergic nuclei.

The dopaminergic pathway is linked to cAMP intracellular signalling in both brainstem and olfactory system; TH is induced by the cAMP-mediated signalling pathway [34]. In PD substantia nigra, both D1 receptors and DARPP32 appear downregulated [35]. Dopaminergic neurons are protected against MPTP toxicity after the inhibition of monoaminoxidase-B, which acts via PKA [36]. Moreover, substantia nigra is protected from MPTP by phosphodiesterase inhibitors, that enhance cAMP and subsequently PKA [37]. Here, the transient increase in OB PKA after MPTP may be linked to a protective response in these neurons, opening a new challenge for neuroprotection in other brain areas.

PKA participates also in reaction to MPTP, so that in lesioned mice activation of PKA with forskolin induces an exaggerated increase in TH [38]. Moreover, glutamatergic corticostriatal pathway is overactive after nigrostrial denervation, and subsequently striatal PKA-dependent NMBA phosphorylation increases [39]. Striatal deafferentation increases neurogenesis in the olfactory bulb, mostly for new dopaminergic cells [40, 41]. In our MPTP mice, the PKA transient increase in OB inner granular layer, which hosts also the developing new neurons coming from the subventricular zone, suggests an upregulation of the cAMP-mediated signalling in response to MPTP, which should be studied in greater detail.

The differential effects of MPTP in OB neurons were related to the lack of the dopamine transporter, which uptakes the toxic MPTP metabolite, making OB neurons MPTP-resistant [42]. While further studies, including other animal PD models like 6-OHDA, are needed, the present data confirm that TH immunoreactivity is not affected in the OB after MPTP injection. However, we challenge the idea that the olfactory system is not affected by MPTP at all, since a decrease in OMP and a transient increase in PKA RII were consistently observed, suggesting a specific response to MPTP in OB neurons, that is not apparent in the nigra, and could be exploited for therapeutic purposes.

### Abbreviations

ANOVA: analysis of variance; GABA: gamma-aminobutyric acid; MPTP: 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine; OB: olfactory bulb; OMP: Olfactory Marker Protein; PBS: phosphate buffered saline; PD: Parkinson’s disease; PKA: cAMP-dependent protein kinase; R: regulatory subunit of PKA; SAF-cAMP: 8-thioacetamido-fluorescein-cAMP; TH: tyrosine hydroxylase.

### Authors’ contributions

Conceived project, designed and performed experiments: CM and AC. Wrote manuscript: CM. Both authors read and approved the final manuscript.

### Author details

1 Department of Molecular Medicine, University of Padova, Via Marzolo, 3, 35131 Padua, Italy. 2 INBB, National Institute of Biostructures and Biosystems, Rome, Italy. 3 Department of Pharmacy, University of Parma, Parma, Italy.

### Acknowledgements

We thank Michela Bondi for data collection and Marco Redaelli for video analysis.

### Competing interests

The authors declare that they have no competing interests.

### Availability of data and materials

All data generated or analysed during this study are included in this manuscript.

### Ethics approval and consent to participate

The experiments were authorized according to the directive 86/609/EEC and approved by the Italian Ministry of Health and by the University of Padova ethical committee.

### Funding

This work was supported by the University of Padova and the Italian Ministry of Research (PRIN Project 2010599KBR).
References

1. Hawkes CH, Shephard BC, Daniel SE. Olfactory dysfunction in Parkinson's disease. J Neurol Neurosurg Psychiatry. 1997;62:436–46.

2. Braak H, Ghebremedhin E, Rub U, Bratzke H, Del Tredici K. Stages in the development of Parkinson's disease-related pathology. Cell Tissue Res. 2004;318:121–34.

3. Del Tredici K, Rub U, De Vos RA, Bohl JH, Braak H. Where does Parkinson's disease pathology begin in the brain? J Neuropathol Exp Neurol. 2002;61:413–26.

4. Pearce RK, Hawkes CH, Daniel SE. The anterior olfactory nucleus in Parkinson's disease. Mov Disord. 1995;10:283–8.

5. Daniel SE, Hawkes CH. Preliminary diagnosis of Parkinson's disease by olfactory bulb pathology. Lancet. 1992;340:186.

6. Koster NL, Norman AB, Richtand NM, Nickell WT, Puche AC, Pixley SK, Shipley MT. Olfactory receptor neurons express D2 dopamine receptors. J Comp Neurol. 1999;411:666–73.

7. Gutierrez-Alecanas M, Crespo C, Basco-Ibanez JM, Gacia-Llanes FJ, Marques-Mari AI, Nacher J, Varea E, Martinez-Guajardo FL. Distribution of D2 dopamine receptor in the olfactory glomeruli of the rat olfactory bulb. Eur J Neurosci. 2005;22:1357–67.

8. Mania-Farnell BL, Farbman AI, Bruch RC. Bromocriptine, a dopamine D2 receptor agonist, inhibits adenyl cyclase activity in rat olfactory epithelium. Neuroscience. 1993;57:173–80.

9. Bruening I, Sommer M, Hatt B, Borkmann J. Dopamine receptor subtypes modulate olfactory bulb gamma-aminobutyric acid type A receptors. Proc Natl Acad Sci USA. 1999;96:2456–60.

10. Liu Z, Jang J, Jei I, Guo L. A novel mechanism of dopamine neurotoxicity involving the peripheral extracellular and the plasma membrane dopamine transporter. NeuroReport. 2001;12:3293–7.

11. Riederer P, Luborzewski A, God R, Bringmann G, Scholz J, Feineis D, Riederer F. Modification of tyrosine hydroxylase activity by chloral derived β-carbolines in vitro. J Neurochem. 2002;81:814–9.

12. Oh JD, Del Dotto P, Chase TN. Protein kinase A inhibitor attenuates levodopa-induced motor response alterations in the hemiparkinsonian rat. Neurosci Lett. 1997;228:5–8.

13. FeiblingE T, Sebastianutto I, Alcacer C, FeiblingE T, Sebastianutto I, Alcacer C, Bimpisidis Z, Maslava N, Sandberg S, Engblom D, Cenci MA, et al. Mechanisms of dopamine D1 receptor-mediated ERK1/2 activation in the parkinsonian striatum and their modulation by metabolic glutamate receptor type S. J Neurosci. 2014;34:4728–40.

14. Kawahata I, Ohtaku S, Tomioka Y, Ichinose H, Yamakuni T. Dopamine depletion impairs precursor cell proliferation in Parkinson's disease. Mov Disord. 2009;651:15–35.

15. Mucignat-Caretta C, Bondi M, Caretta A. Animal models of depression: olfactory lesions affect amygdala, subventriclezal zone, and aggression. Neurobiol Dis. 2004;16:386–95.

16. Sedelis M, Schwarting RKW, Huston JP. Behavioral phenotyping of the MPTP mouse model of Parkinson's disease. Behav Brain Res. 2001;125:109–22.

17. Mucignat-Caretta C, Caretta A. Regional variations in the localization of insoluble kinase A regulatory isoforms during rodent brain development. J Chem Neuroanat. 2004;27:201–12.

18. Braak H, Del Tredici K, Rub U, de Vos RA, Jansen Steur EN, Braak E. Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol Aging. 2003;24:197–211.

19. Asakawa T, Fang H, Sugiyama K, Nozaki T, Hong Z, Yang Y, Hua F, Ding G, Chao D, Fenoy A, Villarreal SJ, Oneo H, Suzuki K, Mori N, Namba H, Xia Y. Animal behavioral assessments in current research of Parkinson's disease. Neurosci Biobehav Rev. 2016;65:63–94.

20. Antony PMA, Diederich NJ, Balling R. Parkinson's disease mouse models in translational research. Mamm Genome. 2011;22:401–19.

21. Kuroski R, Muramatsu Y, Kato H, Araki T. Biochemical, behavioral and immunohistochemical alterations in MPTP-treated mouse model of Parkinson's disease. Pharmacol Biochem Behav. 2004;78:143–53.

22. Doty RL, Singh A, Tetruad J, Langston JW. Lack of major olfactory dysfunction in MPTP-induced parkinsonism. Ann Neurol. 1992;32:97–100.

23. Kurtenbach S, Weyerling S, Hatt H, Neuhaus EM, Lubbert H. Olfaction in three genetic and two MPTP-induced Parkinson's disease mouse models. PLoS ONE. 2013;8(10):e77509.

24. Brown RG, Jahnahshi M. Cognitive-motor dysfunction in Parkinson's disease. Eur Neurol. 1996;36:24–31.

25. Poewe W. Non-motor symptoms in Parkinson's disease. Eur J Neurol. 2008;15:14–20.

26. Fleming SM, Tetreault NA, Mulligan CK, Hutson CB, Masliah E, Cheselet MF. Olfactory deficits in mice overexpressing human wildtype α-synuclein. Eur J Neurosci. 2008;28:247–56.

27. Xu Z, Cawthron D, McCastlain KA, Slkker W Jr, Ali SF. Selective alterations of gene expression in mice induced by MPTP Sypnase. 2005;55:45–51.

28. Tinti C, Conti S, Cubells JF, Kim KS, Baker H, Joh TH. Inducible cAMP Early Repressor can modulate tyrosine hydroxylase gene expression after stimulation of cAMP synthesis. J Biol Chem. 1996;271:25375–81.

29. Cash R, Raisman P, Ploska A, Agid Y. Dopamine D1 receptor and cyclic AMP-dependent phosphorylation in Parkinson's disease. J Neurochem. 1987;49:1075–83.

30. Andoh T, Chock PB, Murphy DL, Chueh CC. Role of the redox protein thioredoxin in cytoprotective mechanism evoked by (-)-deprenyl. Mol Pharmacol. 2005;68:1408–14.

31. Hulley P, Hartikka J, AbdelKal S, Engels P, Buerki HR, Wiederhold KH, Muller T, Kelly P, Lowe D, Lubbert H. Inhibitors of type IV phosphodiesterases reduce the toxicity of MPTP in substantia nigra neurons in vivo. Eur J Neurosci. 1995;7:2431–40.

32. Young EA, Duchemin AH, Nef NH, Hadjiconstantinou M. Parallel modulation of striatal dopamine synthetic enzymes by second messenger pathways. Eur J Pharmacol. 1998;357:15–23.

33. Betarbet R, Poisik O, Sherer TB, Greenamyre JT. Differential expression and Ser 897 phosphorylation of striatal N-methyl-d-aspartate receptor subunit NR1 I in animal models of Parkinson's disease. Exp Neurol. 2004;187:76–85.

34. Yamada M, Ondorea M, Izuuno Y, Mochizuki H. Neurogenesis in olfactory bulb identified by retroviral labeling in normal and 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated adult mice. Neuroscience. 2004;124:173–81.

35. Winner B, Geyer M, Coullard-Despres S, Aigner R, Bogdahn U, Aigner L, Kuhn G, Winkler J. Striatal deafferentation increases dopaminergic neurogenesis in the adult olfactory bulb. Exp Neurol. 2006;197:113–21.

36. Mitsumoto Y, Mori A, Ohashi S, Nakai M, Morizumi T. Differential effects of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in the olfactory bulb and the striatum in mice. Neurosci Res. 2005;51:111–5.